Aptevo has reported an 87% clinical benefit and 81% remission rate in 31 evaluable frontline AML patients through Cohort 5, significantly outperforming benchmarks. The RAINIER study is on track for completion in 2026, with plans for Phase 2 dose selection.
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection | APVO Stock News